Literature DB >> 10344732

D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability.

K E Knudsen1, W K Cavenee, K C Arden.   

Abstract

D-type cyclins regulate distinct cellular processes, such as mitotic cell cycle control, differentiation, and transcription. We have previously shown that the D-type cyclins are critical for the androgen-dependent proliferation of prostate cells. Here, we sought to determine whether cyclin D1 directly influences the transactivation potential of the androgen receptor, a transcription factor that strongly influences androgen-dependent proliferation. We found that ligand-mediated transcriptional activation of a physiological target, prostate-specific antigen, by the androgen receptor was inhibited by cyclins D1 and D3. The ability of D-type cyclins to inhibit androgen receptor transactivation was not shared with other cyclins, and cyclin D1 was as effective as dominant negative mutants of the androgen receptor in inhibiting transactivation. This function of cyclin D1 was independent of its role in cell cycle progression and is likely elicited through its ability to form a specific complex with the androgen receptor. These data underscore the various mechanisms through which the androgen receptor is regulated and also point to a negative feedback role for cyclin D1 in controlling androgen-dependent growth.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10344732

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  69 in total

Review 1.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

2.  Evidence for CDK-dependent and CDK-independent functions of the murine gammaherpesvirus 68 v-cyclin.

Authors:  Jason W Upton; Samuel H Speck
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

Review 3.  Cyclins, cyclin dependent kinases, and regulation of steroid receptor action.

Authors:  N L Weigel; N L Moore
Journal:  Mol Cell Endocrinol       Date:  2007-01-05       Impact factor: 4.102

4.  Transgenic expression of cyclin-dependent kinase 4 results in epidermal hyperplasia, hypertrophy, and severe dermal fibrosis.

Authors:  P L Miliani de Marval; I B Gimenez-Conti; M LaCava; L A Martinez; C J Conti; M L Rodriguez-Puebla
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 5.  Integration of progesterone receptor action with rapid signaling events in breast cancer models.

Authors:  Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-14       Impact factor: 4.292

6.  Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.

Authors:  Xiaoming Ju; Mathew C Casimiro; Michael Gormley; Hui Meng; Xuanmao Jiao; Sanjay Katiyar; Marco Crosariol; Ke Chen; Min Wang; Andrew A Quong; Michael P Lisanti; Adam Ertel; Richard G Pestell
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

Review 7.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

8.  Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Authors:  Michael A Augello; Craig J Burd; Ruth Birbe; Christopher McNair; Adam Ertel; Michael S Magee; Daniel E Frigo; Kari Wilder-Romans; Mark Shilkrut; Sumin Han; Danielle L Jernigan; Jeffry L Dean; Alessandro Fatatis; Donald P McDonnell; Tapio Visakorpi; Felix Y Feng; Karen E Knudsen
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

Review 9.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

10.  Cyclin D3 promotes pancreatic β-cell fitness and viability in a cell cycle-independent manner and is targeted in autoimmune diabetes.

Authors:  Noemí Alejandra Saavedra-Ávila; Upasana Sengupta; Begoña Sánchez; Ester Sala; Laura Haba; Thomas Stratmann; Joan Verdaguer; Dídac Mauricio; Belén Mezquita; Ana Belén Ropero; Ángel Nadal; Conchi Mora
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.